CA2486001C - Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity - Google Patents

Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity Download PDF

Info

Publication number
CA2486001C
CA2486001C CA2486001A CA2486001A CA2486001C CA 2486001 C CA2486001 C CA 2486001C CA 2486001 A CA2486001 A CA 2486001A CA 2486001 A CA2486001 A CA 2486001A CA 2486001 C CA2486001 C CA 2486001C
Authority
CA
Canada
Prior art keywords
compositions
degree
hours
temperature
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2486001A
Other languages
English (en)
French (fr)
Other versions
CA2486001A1 (en
Inventor
Alberto Bernareggi
Valeria Livi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Les Laboratoires Servier SAS
CTI Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS, CTI Biopharma Corp filed Critical Les Laboratoires Servier SAS
Publication of CA2486001A1 publication Critical patent/CA2486001A1/en
Application granted granted Critical
Publication of CA2486001C publication Critical patent/CA2486001C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2486001A 2002-05-16 2003-05-09 Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity Expired - Lifetime CA2486001C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2002MI001040A ITMI20021040A1 (it) 2002-05-16 2002-05-16 Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale
ITMI2002A001040 2002-05-16
PCT/EP2003/004871 WO2003097101A1 (en) 2002-05-16 2003-05-09 Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity

Publications (2)

Publication Number Publication Date
CA2486001A1 CA2486001A1 (en) 2003-11-27
CA2486001C true CA2486001C (en) 2010-04-13

Family

ID=11449903

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2486001A Expired - Lifetime CA2486001C (en) 2002-05-16 2003-05-09 Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity

Country Status (12)

Country Link
US (3) US20060199831A1 (https=)
EP (1) EP1503797B1 (https=)
JP (1) JP4624780B2 (https=)
AT (1) ATE381944T1 (https=)
AU (1) AU2003240613A1 (https=)
CA (1) CA2486001C (https=)
DE (1) DE60318310T2 (https=)
ES (1) ES2298521T3 (https=)
FR (1) FR12C0064I2 (https=)
IT (1) ITMI20021040A1 (https=)
MX (1) MXPA04011348A (https=)
WO (1) WO2003097101A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2106788A1 (en) * 2008-04-04 2009-10-07 Ipsen Pharma Liquid and freeze dried formulations
CN108113967A (zh) * 2016-03-26 2018-06-05 夏建明 一种治疗非霍奇金淋巴瘤的冻干组合物及其制备方法
CN105769757B (zh) * 2016-03-26 2018-05-25 青岛市肿瘤医院 一种治疗非霍奇金淋巴瘤的注射液及其制备方法
CN105997896B (zh) * 2016-05-28 2019-07-05 长沙秋点兵信息科技有限公司 治疗非霍奇金淋巴瘤的注射用冻干粉及其制备方法
CN106176630B (zh) * 2016-08-03 2019-01-04 湖北丽益医药科技有限公司 一种注射用马来酸匹杉琼无菌粉末的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3590124A (en) * 1967-06-27 1971-06-29 Us Navy Blood transfusion fluids having reduced turbulent friction properties
JP2690009B2 (ja) * 1986-07-10 1997-12-10 エーザイ 株式会社 セフアロスポリン注射剤
NZ241868A (en) 1991-03-08 1995-05-26 Univ Vermont 6,9-bis(substituted-amino)benzo[g]isoquinoline-5,10-diones, preparation and pharmaceutical compositions thereof
JP3501471B2 (ja) * 1992-06-15 2004-03-02 旭化成ファーマ株式会社 カルシトニン類の安定化組成物および安定化法
JPH08126685A (ja) * 1994-01-26 1996-05-21 Shionogi & Co Ltd デキストラン類の凍結乾燥方法
US5587382A (en) * 1994-03-28 1996-12-24 Boehringer Mannheim Italia, Spa 6,9-bis[(2-aminoethyl) amino]benzo [g]isoquinoline-5,10- dione dimaleate; an aza-anthracenedione with reduced cardiotoxicity
PT1030839E (pt) * 1997-11-10 2004-05-31 Searle & Co Utilizacao de iminoacucares para tratar a resistencia a multifarmacos
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
IT1315253B1 (it) * 1999-10-22 2003-02-03 Novuspharma Spa Preparazione liposomiale di 6,9-bis-(2-amminoetil)ammino|benzog|isochinolin-5,10-dione dimaleato

Also Published As

Publication number Publication date
US20110144147A1 (en) 2011-06-16
CA2486001A1 (en) 2003-11-27
EP1503797B1 (en) 2007-12-26
FR12C0064I2 (fr) 2013-08-16
MXPA04011348A (es) 2005-08-15
US9211262B2 (en) 2015-12-15
DE60318310T2 (de) 2008-12-11
ITMI20021040A0 (it) 2002-05-16
FR12C0064I1 (https=) 2012-12-14
ES2298521T3 (es) 2008-05-16
AU2003240613A1 (en) 2003-12-02
US20060199831A1 (en) 2006-09-07
ITMI20021040A1 (it) 2003-11-17
JP4624780B2 (ja) 2011-02-02
US20160256557A1 (en) 2016-09-08
DE60318310D1 (de) 2008-02-07
ATE381944T1 (de) 2008-01-15
JP2005530792A (ja) 2005-10-13
WO2003097101A1 (en) 2003-11-27
EP1503797A1 (en) 2005-02-09

Similar Documents

Publication Publication Date Title
EP3542812B1 (en) Glycopeptide compositions
EP3228319B1 (en) Lyophilized preparation of cytotoxic dipeptides
US20160256557A1 (en) Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity
JP6832281B2 (ja) バンコマイシンの水溶液製剤
WO2022129264A1 (en) Aqueous solution
CA3040018A1 (en) Pharmaceutical parenteral formulation containing carglumic acid
WO2022129263A1 (en) Aqueous solution
AU1769501A (en) Stable amorphous amifostine composition, and preparation thereof
US5972912A (en) Method for lyophilizing ifosfamide
IL280812B2 (en) A lyophilic preparation of cytotoxic dipeptides
EP4070785B1 (en) Lyophilized composition of copanlisib salt
WO2023214433A1 (en) Stable parenteral compositions of parecoxib
US20150284421A1 (en) Formulation of 5-azacytidine
HK40081253A (en) Lyophilized preparation of cytotoxic dipeptides
HK40018864A (en) Lyophilized preparation of cytotoxic dipeptides
HK1245124B (en) Lyophilized preparation of cytotoxic dipeptides
HK1245124A1 (en) Lyophilized preparation of cytotoxic dipeptides

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20230509